ARC-HBR 高出血风险标准
用途适用: before/at PCI when choosing stent strategy and DAPT duration.
分层Binary HBR definition (~≥4% 1-year BARC 3/5 or ≥1% ICH). More criteria → higher risk.
局限不适用: to withhold indicated PCI for ACS. · 易错点: scoring both major and minor CKD/anemia bands for the same patie… · Pair with ischemic risk (e.g. PRECISE-DAPT context).
出处Urban P, et al. Circulation 2019 (ARC-HBR)
本班次下一步
评完分数后:进场景连算、看相邻评分、打开对应路径。本地参考,不写入 HIS。
方法学 · 公式代入、指南要点与完整说明
适用场景
适用: before/at PCI when choosing stent strategy and DAPT duration.
需要填写的项目
- Major: anticipated long-term oral anticoagulation · 选项
- Major: severe/end-stage CKD (eGFR < 30) · 选项
- Major: hemoglobin < 11 g/dL · 选项
- Major: spontaneous bleed needing hosp/transfusion in past 6 mo (or any time if recurrent) · 选项
- Major: platelets < 100×10⁹/L · 选项
- Major: chronic bleeding diathesis · 选项
- Major: cirrhosis with portal hypertension · 选项
- Major: active malignancy (excl. nonmelanoma skin) within 12 mo · 选项
- Major: prior spontaneous ICH (any time); traumatic ICH <12 mo; bAVM; or mod/severe ischemic stroke <6 mo · 选项
- Major: nondeferrable major surgery on DAPT · 选项
- Major: major surgery or major trauma within 30 d before PCI · 选项
- Minor: age ≥ 75 y · 选项
- Minor: moderate CKD (eGFR 30–59) · 选项
- Minor: Hb 11–12.9 (men) or 11–11.9 (women) g/dL · 选项
- Minor: spontaneous bleed needing hosp/transfusion in past 12 mo (not meeting major) · 选项
- Minor: long-term oral NSAIDs or steroids · 选项
- Minor: any prior ischemic stroke not meeting major criterion · 选项
计算方法与公式
HBR if ≥1 major OR ≥2 minor consensus criteria (Urban 2019 table).
Check mutually exclusive CKD/Hb/bleed/stroke pairs carefully so major and minor are not double-counted inappropriately.
公式代入演示
下列数值取自本工具各输入项的示例值,用本页公式在服务端实际算出,供快速核对计算过程。仅演示代入方法,不构成临床建议,也不代表任何真实病例。
| Major: anticipated long-term oral anticoagulation | 否 (0) |
|---|---|
| Major: severe/end-stage CKD (eGFR < 30) | 否 (0) |
| Major: hemoglobin < 11 g/dL | 否 (0) |
| Major: spontaneous bleed needing hosp/transfusion in past 6 mo (or any time if recurrent) | 否 (0) |
| Major: platelets < 100×10⁹/L | 否 (0) |
| Major: chronic bleeding diathesis | 否 (0) |
| Major: cirrhosis with portal hypertension | 否 (0) |
| Major: active malignancy (excl. nonmelanoma skin) within 12 mo | 否 (0) |
| Major: prior spontaneous ICH (any time); traumatic ICH <12 mo; bAVM; or mod/severe ischemic stroke <6 mo | 否 (0) |
| Major: nondeferrable major surgery on DAPT | 否 (0) |
| Major: major surgery or major trauma within 30 d before PCI | 否 (0) |
| Minor: age ≥ 75 y | 否 (0) |
| Minor: moderate CKD (eGFR 30–59) | 否 (0) |
| Minor: Hb 11–12.9 (men) or 11–11.9 (women) g/dL | 否 (0) |
| Minor: spontaneous bleed needing hosp/transfusion in past 12 mo (not meeting major) | 否 (0) |
| Minor: long-term oral NSAIDs or steroids | 否 (0) |
| Minor: any prior ischemic stroke not meeting major criterion | 否 (0) |
→ARC-HBRNot HBR
- Major criteria:0
- Minor criteria:0
- Rule:≥1 major OR ≥2 minor = HBR
| Major: anticipated long-term oral anticoagulation | 是 — 主要 |
|---|---|
| Major: severe/end-stage CKD (eGFR < 30) | 是 — 主要 |
| Major: hemoglobin < 11 g/dL | 是 — 主要 |
| Major: spontaneous bleed needing hosp/transfusion in past 6 mo (or any time if recurrent) | 是 — 主要 |
| Major: platelets < 100×10⁹/L | 是 — 主要 |
| Major: chronic bleeding diathesis | 是 — 主要 |
| Major: cirrhosis with portal hypertension | 是 — 主要 |
| Major: active malignancy (excl. nonmelanoma skin) within 12 mo | 是 — 主要 |
| Major: prior spontaneous ICH (any time); traumatic ICH <12 mo; bAVM; or mod/severe ischemic stroke <6 mo | 是 — 主要 |
| Major: nondeferrable major surgery on DAPT | 是 — 主要 |
| Major: major surgery or major trauma within 30 d before PCI | 是 — 主要 |
| Minor: age ≥ 75 y | 是 — 次要 |
| Minor: moderate CKD (eGFR 30–59) | 是 — 次要 |
| Minor: Hb 11–12.9 (men) or 11–11.9 (women) g/dL | 是 — 次要 |
| Minor: spontaneous bleed needing hosp/transfusion in past 12 mo (not meeting major) | 是 — 次要 |
| Minor: long-term oral NSAIDs or steroids | 是 — 次要 |
| Minor: any prior ischemic stroke not meeting major criterion | 是 — 次要 |
→ARC-HBRHBR positive
- Major criteria:11
- Minor criteria:6
- Rule:≥1 major OR ≥2 minor = HBR
结果判读与分层
Binary HBR definition (~≥4% 1-year BARC 3/5 or ≥1% ICH). More criteria → higher risk.
指南要点(原创整理)
- ≥1 major or ≥2 minor.
- Consensus criteria.
- 下一步: PRECISE-DAPT / DAPT score / HAS-BLED.
以上为依据相应指南的关键推荐、由本站用自己的语言归纳整理(非指南原文);完整内容请见下方官方来源。
注意事项与局限
- 不适用: to withhold indicated PCI for ACS.
- 易错点: scoring both major and minor CKD/anemia bands for the same patient.
- Pair with ischemic risk (e.g. PRECISE-DAPT context).
核对与出处 · 可验证治理
参考指南与出处
- Urban P, et al. Circulation 2019 (ARC-HBR) · 来源 ↗
指南全文版权归相应学会/期刊所有;本工具仅实现其决策算法并注明出处,全文请经上方官方来源获取。
依据文献年份见参考 · 数据集整理日 2026-10-08
常见问题
常见问题
- ARC-HBR 高出血风险标准的计算是否上传患者数据?在哪里计算?
- 计算在浏览器本地完成,输入与结果不上传服务器;结果仅供执业医师参考,须结合病史、检查与本机构方案判断,不构成诊断或处方依据。
- ARC-HBR 高出血风险标准怎么代入计算?能举个例子吗?
- 代入: Major: anticipated long-term oral anticoagulation 否 (0)、Major: severe/end-stage CKD (eGFR < 30) 否 (0)、Major: hemoglobin < 11 g/dL 否 (0)、Major: spontaneous bleed needing hosp/transfusion in past 6 mo (or any time if recurrent) 否 (0)、Major: platelets < 100×10⁹/L 否 (0)、Major: chronic bleeding diathesis 否 (0)、Major: cirrhosis with portal hypertension 否 (0)、Major: active malignancy (excl. nonmelanoma skin) within 12 mo 否 (0)… → 结果: ARC-HBR Not HBR(Major criteria: 0、Minor criteria: 0、Rule: ≥1 major OR ≥2 minor = HBR) 代入: Major: anticipated long-term oral anticoagulation 是 — 主要、Major: severe/end-stage CKD (eGFR < 30) 是 — 主要、Major: hemoglobin < 11 g/dL 是 — 主要、Major: spontaneous bleed needing hosp/transfusion in past 6 mo (or any time if recurrent) 是 — 主要、Major: platelets < 100×10⁹/L 是 — 主要、Major: chronic bleeding diathesis 是 — 主要、Major: cirrhosis with portal hypertension 是 — 主要、Major: active malignancy (excl. nonmelanoma skin) within 12 mo 是 — 主要… → 结果: ARC-HBR HBR positive(Major criteria: 11、Minor criteria: 6、Rule: ≥1 major OR ≥2 minor = HBR)
核对流程与方法学
核对与依据
本工具的公式与计算方法已在本页明示、公开可逐一核查。其公式、系数与阈值依据上方「参考指南与出处」列出的权威来源核对。想了解本站对全部临床工具的核对流程与出处覆盖情况,见 临床工具核对表与方法学 →